Answers are grounded in this paper and cite their sources.
Although the role of eltrombopag in the second-line treatment of ITP is solid, there are insufficient data regarding response rates with the use of TPO-RAs in later lines.The main aim of our study was to evaluate the results obtained with the preference of eltrombopag according to the line of treatment in patients diagnosed with ITP.
No takes yet. Share an insight, caveat, or question.
Karışmaz et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: